Baseline Spleen Volume is Independently Associated With Survival After CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Measuring spleen size on imaging may help identify CAR-T therapy candidates most likely to survive, improving how doctors select patients for this intensive treatment.
This cohort study identified baseline spleen volume as an independent prognostic biomarker for survival after CD19 CAR-T cell therapy in r/r DLBCL. The finding introduces a clinically accessible imaging measure that could improve CAR-T patient selection and risk stratification in a field with highly variable outcomes.
What the study was
- Study design
- Retrospective cohort study
- Population
- r/r DLBCL patients receiving CD19-directed CAR-T cell therapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Hematological oncology
Why it surfaced
Novel imaging biomarker for CAR-T patient selection in DLBCL; immediately applicable to this rapidly expanding and resource-intensive therapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.